References
- Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955–1959.
- Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61(10):1558–1565.
- De Leonardis F, Novielli C, Giannico B. Isavuconazole treatment of cerebral and pulmonary aspergillosis in a pediatric patient with Acute lymphoblastic leukemia: case report and review of literature. J Pediatr Hematol Oncol. 2019: DOI: 10.1097/MPH.0000000000001508.
- Lamoth F, Mercier T, André P, et al. Isavuconazole brain penetration in cerebral aspergillosis. J Antimicrob Chemother. 2019;74(6):1751–1753.
- Li M, Zhu L, Chen L, et al. Assessment of drug-drug interactions between voriconazole and glucocorticoids. J Chemother. 2018;30(5):296–303.
- Schmitt-Hoffman AH, Kato K, Townsend RT, et al. Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats. Antimicrob Agents Chemother. 2017;61(12):e01292–17.
- Lee A, Prideaux B, Lee MH, et al. Tissue distribution and penetration of isavuconazole at the site of infection in experimental invasive aspergillosis in mice with underlying chronic granulomatous disease. Antimicrob. Agents Chemother. 2019;63(6):e00524–19.